Cabaletta Bio announced its Q1 2026 financial results and highlighted key advances in its autoimmune disease cell therapy, rese-cel. The company presented promising 6-to-9-month clinical data without preconditioning for pemphigus vulgaris patients and expanded commercial manufacturing through a 10-year supply deal with Cellares. Patient enrollment is progressing in pivotal trials for myositis, with plans for a Biologics License Application (BLA) submission in 2027. Additionally, Cabaletta raised $150 million in a recent financing, supporting its development and potential commercial launch of rese-cel into mid-2027.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
Wendy's is running a $1 promotion on small Classic Chocolate or Vanilla Frosty from July 20 to August 23, with early access for Wendy's Rewards members on July 19 in celebration of National Ice Cream Day. The offer is redeemable via the Wendy's app a...
Inseego Corp. will release its financial results for the second quarter of 2026 on August 5, after market close. The company will hold a conference call the same day to discuss the results and business outlook. Investors can access the earnings repor...
Dyadic International has expanded its bio-industrial pipeline with a new proprietary enzyme program focused on advanced cellulose processing, building on the success of its EN3ZYME™ product. This initiative leverages Dyadic's Dapibus™ platform to str...
